Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Department of Obstetrics and Gynecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
BJOG. 2024 Dec;131(13):1851-1861. doi: 10.1111/1471-0528.17919. Epub 2024 Jul 25.
A Serous Tubal Intraepithelial Carcinoma (STIC) without concomitant invasive carcinoma is occasionally identified and associated with a high risk of subsequent peritoneal carcinomatosis. Management needs optimisation. This study explores professionals' opinions and clinical practices regarding the diagnosis, counselling, treatment and follow-up of isolated STIC to facilitate clinical decision making and optimise the direction of future research. A secondary aim is to assess international clinical guidelines.
Focus group study.
Four online sessions.
International panel (n = 12 countries) of gynaecologists, gynaecologic oncologists, pathologists and medical oncologists (n = 49).
A semi-structured interview guide was used. Two independent researchers analysed transcripts by open and axial coding. Results were organised in domains. Relevant (inter)national guidelines were screened for recommendations regarding isolated STIC.
Professionals' opinions and clinical practices regarding isolated STIC management.
Regarding pathology, most professionals identified the SEE-FIM protocol as standard of care for high-risk patients, whereas variation exists in the histopathological examination of fallopian tubes in the general population. Confirmation of STIC diagnosis by a specialised pathologist was recommended. Regarding work-up and follow-up after STIC diagnosis, there was variety and discordance. Data on outcomes is limited. As for treatment, chemotherapy and PARP inhibitors were not recommended by most. Eleven guidelines provided limited recommendations.
We identified recommendations and highlighted knowledge gaps in the diagnosis and management of isolated STIC. Moreover, recommendations in clinical guidelines are limited. There is an agreed need for international collaboration for the prospective registration of isolated STIC.
偶尔会发现没有伴发浸润性癌的输卵管上皮内癌(STIC),且其与随后发生腹膜癌病的风险较高相关。需要对其进行优化管理。本研究旨在探讨专业人员对孤立性 STIC 的诊断、咨询、治疗和随访的意见和临床实践,以促进临床决策并优化未来研究方向。次要目标是评估国际临床指南。
焦点小组研究。
四个在线会议。
国际妇科医生、妇科肿瘤学家、病理学家和肿瘤内科医生小组(n=49,来自 12 个国家)。
采用半结构化访谈指南。两位独立研究人员通过开放性和轴向编码分析转录本。结果以域的形式呈现。为了确定有关孤立性 STIC 的建议,对相关(国际)指南进行了筛选。
专业人员对孤立性 STIC 管理的意见和临床实践。
关于病理学,大多数专业人员将 SEE-FIM 方案确定为高危患者的标准护理,而在普通人群中对输卵管的组织病理学检查则存在差异。建议由专门的病理学家确认 STIC 诊断。关于 STIC 诊断后的检查和随访,存在多样性和不一致性。关于结局的数据有限。至于治疗,大多数人不推荐化疗和 PARP 抑制剂。十一份指南提供了有限的建议。
我们确定了孤立性 STIC 的诊断和管理方面的建议和知识空白。此外,临床指南中的建议是有限的。国际合作前瞻性登记孤立性 STIC 的需求得到了一致认可。